These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6233076)

  • 1. [Controlled clinical study on 2 antialdosterone diuretics in the nephrotic syndrome].
    Russo R; Schena FP; Colombo Pirola L
    Clin Ter; 1984 Apr; 109(1):23-9. PubMed ID: 6233076
    [No Abstract]   [Full Text] [Related]  

  • 2. [Controlled study of the effect of long-term administration of canrenoate potassium in cirrhotic ascites].
    Traina M; Vizzini GB
    Minerva Med; 1986 Jan; 77(3-4):87-91. PubMed ID: 3511409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of diuretics in preventing ascites recurrence.
    Arrigoni A; Andriulli A; Gindro T; Verme G
    Br J Clin Pract; 1988 Mar; 42(3):116-20. PubMed ID: 3207572
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC; Bräuninger HJ
    MMW Munch Med Wochenschr; 1975 Sep; 117(37):1483-6. PubMed ID: 810673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical study of spironolactone and potassium canrenoate. A randomized evaluation with double cross-over.
    Emili M; Cuppone R; Ricci GL
    Arzneimittelforschung; 1988 Oct; 38(10):1492-5. PubMed ID: 3058132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metolazone and spironolactone in cirrhosis and the nephrotic syndrome.
    Lang GR; Westenfelder C; Nascimento L; Dhupelia VB; Arruda JA; Kane RE
    Clin Pharmacol Ther; 1977 Feb; 21(2):234-43. PubMed ID: 319937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperaldosteronism in the acute phase of myocardial infarction. Effects of its treatment on the prevention of ventricular fibrillation].
    Denis B; Dimitriou R; Machecourt J; Wolf JE; Page E; Reboud JP
    Arch Mal Coeur Vaiss; 1984 Apr; 77 Spec No():35-40. PubMed ID: 6428361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of potassium canrenoate in cardiosurgery].
    Tufano R; Scopa M; Brando G; Leone D
    Minerva Anestesiol; 1981 Apr; 47(4):149-54. PubMed ID: 7242963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
    Tosti-Croce C; Mantellini R; Fanti P; Sciarra F
    Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of advanced respiratory insufficiency using potassium canreonate (Aldactone). Preliminary report].
    Kerjaschki A
    Wien Med Wochenschr; 1976 Dec; 126(49-50):705-7. PubMed ID: 795170
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of potassium canrenoate on arterial pressure, plasma renin activity and urinary aldosterone in essential hypertension].
    Opocher G; Armanini D; Fallo F; Mantero F
    Boll Soc Ital Cardiol; 1978; 23(10):1757-66. PubMed ID: 400390
    [No Abstract]   [Full Text] [Related]  

  • 14. [Value of Soludactone in cardiac surgery in adults].
    Fogliani J; Capuccio P; Goudard A; Guillen JC; Monties JR
    Ann Anesthesiol Fr; 1975; 16(3):189-96. PubMed ID: 241276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aldosterone antagonists in coronary insufficiency].
    Osswald H
    Med Klin; 1978 Jan; 73(3):84-8. PubMed ID: 622061
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of digitalis toxicity with intravenous potassium canrenoate.
    Gavrilescu G; Cristodorescu R; Deutsch G; Berger E
    Agressologie; 1977; 18(3):167-71. PubMed ID: 920909
    [No Abstract]   [Full Text] [Related]  

  • 17. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
    Sarti F; Milandri GL; Piemontese A; Macchia S; Simoni S; Dal Monte PR
    Minerva Dietol Gastroenterol; 1984; 30(3):273-80. PubMed ID: 6504377
    [No Abstract]   [Full Text] [Related]  

  • 18. [Efficacy of canrenoate potassium in hypertensive cardiopathy. Clinical and echocardiographic evaluation].
    Caporicci D; Achilli L
    Minerva Cardioangiol; 1984 Sep; 32(9):581-7. PubMed ID: 6514202
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapeutic effect of canrenoate potassium (soldactone) in patients after open-heart surgery].
    Matsuda K; Tatsuta N; Konishi Y; Minami K; Nishiwaki N; Yamasato A; Chiba Y; Ishihara H; Murata S; Shiraishi Y; Muraguchi T; Hikasa Y
    Nihon Geka Hokan; 1982 May; 51(3):519-27. PubMed ID: 7138201
    [No Abstract]   [Full Text] [Related]  

  • 20. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension].
    Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T
    Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.